A Phase 2 interventional study of lurbinectedin (PM01183) in Advanced Solid Tumors, sponsored by PharmaMar. Completed at 40 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.
Sponsored by PharmaMar · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors
Patients with relapsed small cell lung cancer (SCLC), head and neck carcinoma (H\&N), neuroendocrine tumors (NETs), biliary tract carcinoma, endometrial carcinoma, BRCA 1/2-associated metastatic breast carcinoma, carcinoma of unknown primary site, germ cell tumors (GCTs), and Ewing's family of tumors (EFTs) will be enrolled in nine different cohorts. Up to 25 evaluable patients are planned to be enrolled in each cohort (50 in the endometrial carcinoma and 100 in the SCLC cohort).
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
proven diagnosis of any of the following :
Prior treatment. Patients must have received:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
Drug: lurbinectedin (PM01183)
Overall Response Rate (ORR)
Overall Response Rate was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): ≥30% decrease in the sum of the longest diameters of target lesions compared with baseline; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD
Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Response by Investigator Assessment
When response is the primary endpoint, and thus all patients must have measurable disease to enter the trial, all patients included in the study must be accounted for in the report of the results, even if there are major protocol treatment deviations or if they are not evaluable. Each patient will be assigned one of the following: Complete Response: Disappearance of all target lesions; Partial Response: ≥30% decrease in the sum of the longest diameters of target lesions; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD; Inevaluable for response: specify reasons (for example: early death, malignant disease, toxicity; tumour assessments not repeated/incomplete; other). Normally, all eligible patients should be included in the denominator for the calculation of the response rate for phase II trials.
Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Duration of Response
Duration of Response by Investigator's Assessment, defined as the time between the date when the response criteria (PR or CR, whichever one is first reached) are fulfilled to the first date when disease progression (PD), recurrence or death is documented.
Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Clinical Benefit
Clinical Benefit Rate was defined as Overall Response Rate or Stable Disease lasting over four months (SD ≥ 4 months)
Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Disease Control Rate
Disease Control Rate was defined as Overall Response Rate or Stable Disease
Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6
Progression Free Survival (PFS)
Progression-free Survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
Time frame: From the date of first infusion to the date of progression disease, death (of any cause), or last tumor evaluation, up to an average of 5 years
Progression-free Survival at 4 Months
Progression-free Survival at 4, defined as the probability of being free from progression and death after the first infusion at 4 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
Time frame: At 4 months
Progression-free Survival at 6 Months
Progression-free Survival at 6, defined as the probability of being free from progression and death after the first infusion at 6 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
Time frame: At 6 months
Overall Survival (OS)
Overall survival defined as the period of time from the date of first infusion to the date of death or last contact in case of patients lost to follow-up or alive at the clinical cutoff established for the cohort.
Time frame: From the date of first infusion to the date of death or last contact, up to an average of 5 years
Overall Survival at 6 Months
Overall Survival at 6 months defined as the probability of being alive after the first infusion at 6 months
Time frame: At 6 months
Overall Survival at 12 Months
Overall Survival at 12 months defined as the probability of being alive after the first infusion at 12 months
Time frame: At 12 months
The first patient registration was on 25 August 2015 and the first study treatment administration was on 25 August 2015. The last patient registration was on 30 November 2018 and the last study treatment administration was on 29 November 2019. The date of last follow-up (cutoff-date) was 18 September 2020.
| Milestone | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Started | 19 | 19 | 76 | 29 | 24 | 15 | 21 | 32 | 110 |
| Treated | 19 | 19 | 73 | 28 | 23 | 15 | 21 | 32 | 105 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 19 | 19 | 76 | 29 | 24 | 15 | 21 | 32 | 110 |
| Withdrew: Progressive disease | 17 | 16 | 59 | 23 | 16 | 12 | 19 | 27 | 0 |
| Withdrew: Death | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 95 |
| Withdrew: Physician decision | 0 | 1 | 2 | 1 | 2 | 0 | 0 | 1 | 0 |
| Withdrew: Non treatment-related adverse event | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Treatment-related adverse events | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 2 | 0 |
| Withdrew: Patient moves to compassionate use | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 5 | 2 | 3 | 2 | 0 | 1 | 2 |
| Withdrew: Multiple delay/holds on treatment | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Never treated | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Study termination | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
Overall Response Rate was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): ≥30% decrease in the sum of the longest diameters of target lesions compared with baseline; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD
| percentage of participants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 5.6 (0.1 to 27.3) | 0.0 (0.0 to 17.6) | 11.3 (5.0 to 21.0) | 14.3 (4.0 to 32.7) | 4.3 (0.1 to 21.9) | 0.0 (0.0 to 24.7) | 28.6 (11.3 to 55.2) | 6.5 (0.8 to 21.4) | 36.2 (27.0 to 46.1) |
When response is the primary endpoint, and thus all patients must have measurable disease to enter the trial, all patients included in the study must be accounted for in the report of the results, even if there are major protocol treatment deviations or if they are not evaluable. Each patient will be assigned one of the following: Complete Response: Disappearance of all target lesions; Partial Response: ≥30% decrease in the sum of the longest diameters of target lesions; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD; Inevaluable for response: specify reasons (for example: early death, malignant disease, toxicity; tumour assessments not repeated/incomplete; other). Normally, all eligible patients should be included in the denominator for the calculation of the response rate for phase II trials.
| Participants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial Response | 1 | 0 | 6 | 4 | 1 | 0 | 6 | 2 | 38 |
| Stable Disease | 5 | 11 | 29 | 12 | 8 | 3 | 10 | 9 | 34 |
| Progressive disease | 11 | 7 | 30 | 9 | 12 | 8 | 5 | 18 | 28 |
| Inevaluable for response | 1 | 1 | 4 | 3 | 2 | 2 | 0 | 2 | 5 |
Duration of Response by Investigator's Assessment, defined as the time between the date when the response criteria (PR or CR, whichever one is first reached) are fulfilled to the first date when disease progression (PD), recurrence or death is documented.
| months | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Duration of Response | 3.4 (NA to NA) | — | 9.2 (3.4 to 18.0) | 4.2 (2.9 to 5.5) | 10.6 (NA to NA) | — | 8.6 (2.9 to NA) | 4.7 (4.0 to 5.4) | 5.3 (4.1 to 6.2) |
Clinical Benefit Rate was defined as Overall Response Rate or Stable Disease lasting over four months (SD ≥ 4 months)
| percentage of participants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Clinical Benefit | 11.1 (1.4 to 34.7) | 36.8 (16.3 to 61.6) | 35.2 (24.2 to 47.5) | 39.3 (21.5 to 59.4) | 26.1 (10.2 to 48.4) | 15.4 (1.9 to 45.4) | 57.1 (34.0 to 78.2) | 29.0 (14.2 to 48.0) | 45.7 (36.0 to 55.7) |
Disease Control Rate was defined as Overall Response Rate or Stable Disease
| percentage of paticipants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Disease Control Rate | 33.3 (13.3 to 59.0) | 57.9 (33.5 to 79.7) | 52.1 (39.9 to 64.1) | 57.1 (37.2 to 75.5) | 39.1 (19.7 to 61.5) | 23.1 (5.0 to 53.8) | 76.2 (52.8 to 91.8) | 35.5 (19.2 to 54.6) | 68.6 (58.8 to 77.3) |
Progression-free Survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
| months | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 1.3 (1.1 to 2.5) | 2.7 (1.3 to 4.4) | 2.6 (1.4 to 4.0) | 2.7 (1.4 to 4.3) | 1.5 (0.9 to 8.9) | 1.3 (1.2 to 2.1) | 4.1 (2.3 to 6.5) | 1.4 (1.2 to 3.0) | 3.7 (2.6 to 4.3) |
Progression-free Survival at 4, defined as the probability of being free from progression and death after the first infusion at 4 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
| percentage of participants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Progression-free Survival at 4 Months | 13.7 (0.0 to 31.1) | 38.9 (16.4 to 61.4) | 39.7 (28.2 to 51.3) | 46.2 (27.0 to 65.3) | 30.7 (11.0 to 50.4) | 15.4 (0.0 to 35.0) | 57.1 (36.0 to 78.3) | 30.0 (13.6 to 46.4) | 46.5 (36.8 to 56.3) |
Progression-free Survival at 6, defined as the probability of being free from progression and death after the first infusion at 6 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest
| percentage of participants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Progression-free Survival at 6 Months | 13.7 (0.0 to 31.1) | 22.2 (3.0 to 41.4) | 29.0 (18.2 to 39.8) | 23.1 (5.9 to 40.3) | 30.7 (11.0 to 50.4) | 7.7 (0.0 to 22.2) | 33.3 (13.2 to 53.5) | 16.7 (3.3 to 30.0) | 33.4 (24.1 to 42.6) |
Overall survival defined as the period of time from the date of first infusion to the date of death or last contact in case of patients lost to follow-up or alive at the clinical cutoff established for the cohort.
| months | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 7.3 (2.7 to 8.9) | 7.7 (3.8 to 18.8) | 9.3 (6.1 to 12.8) | 12.0 (8.5 to 18.5) | 9.2 (2.7 to 17.4) | 5.7 (2.1 to 12.1) | 16.1 (8.7 to NA) | 7.4 (3.4 to 16.2) | 8.1 (6.5 to 10.9) |
Overall Survival at 6 months defined as the probability of being alive after the first infusion at 6 months
| percentage of participants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Overall Survival at 6 Months | 58.2 (34.5 to 82.0) | 55.6 (32.6 to 78.5) | 62.8 (51.2 to 74.4) | 88.2 (75.7 to 100.0) | 55.0 (32.8 to 77.1) | 38.5 (12.0 to 64.9) | 79.2 (61.0 to 97.4) | 52.1 (33.9 to 70.3) | 68.6 (59.5 to 77.6) |
Overall Survival at 12 months defined as the probability of being alive after the first infusion at 12 months
| percentage of participants | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Overall Survival at 12 Months | 21.8 (0.4 to 43.3) | 36.5 (13.1 to 59.8) | 45.8 (33.8 to 75.9) | 48.5 (27.8 to 69.2) | 34.4 (11.3 to 57.4) | 30.8 (5.7 to 55.9) | 58.1 (35.9 to 80.2) | 38.2 (20.5 to 55.9) | 34.8 (25.5 to 44.1) |
Collected over From the date of first infusion to the date of death or last contact, up to an average of 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurbinectedin (PM01183) | 261/335 (77.9%) | 136/335 (40.6%) | 330/335 (98.5%) |
| Event | Lurbinectedin (PM01183) |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 20/335 |
| NeutropeniaBlood and lymphatic system disorders | 15/335 |
| General physical health deteriorationGeneral disorders | 15/335 |
| ThrombocytopeniaBlood and lymphatic system disorders | 12/335 |
| Abdominal painGastrointestinal disorders | 11/335 |
| AnaemiaBlood and lymphatic system disorders | 10/335 |
| PneumoniaInfections and infestations | 8/335 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/335 |
| VomitingGastrointestinal disorders | 7/335 |
| HyponatraemiaMetabolism and nutrition disorders | 7/335 |
| Event | Lurbinectedin (PM01183) |
|---|---|
| NauseaGastrointestinal disorders | 167/335 |
| AstheniaGeneral disorders | 129/335 |
| FatigueGeneral disorders | 122/335 |
| ConstipationGastrointestinal disorders | 116/335 |
| Decreased appetiteMetabolism and nutrition disorders | 102/335 |
| NeutropeniaBlood and lymphatic system disorders | 89/335 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 77/335 |
| VomitingGastrointestinal disorders | 76/335 |
| DiarrhoeaGastrointestinal disorders | 62/335 |
| AnaemiaBlood and lymphatic system disorders | 59/335 |
Treated patients only
| Age, Categorical(Participants) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 10 | 37 | 27 | 20 | 9 | 19 | 19 | 68 | 222 |
| >=65 years | 6 | 9 | 36 | 1 | 3 | 6 | 2 | 13 | 37 | 113 |
| Age, Continuous(years) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Median | 61 (34 to 74) | 61 (27 to 78) | 64 (32 to 80) | 33 (18 to 74) | 36 (21 to 73) | 62 (39 to 81) | 45 (29 to 73) | 63 (23 to 77) | 60 (40 to 83) | 60 (18 to 83) |
| Sex: Female, Male(Participants) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 10 | 11 | 73 | 12 | 7 | 1 | 21 | 12 | 42 | 189 |
| Male | 9 | 8 | 0 | 16 | 16 | 14 | 0 | 20 | 63 | 146 |
| Race/Ethnicity, Customized(Participants) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| White | 13 | 15 | 45 | 21 | 15 | 12 | 18 | 24 | 79 | 242 |
| Black of African American | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 1 | 7 |
| Asian | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 6 |
| American Indian or Alaska native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Not race available | 6 | 4 | 22 | 4 | 7 | 2 | 3 | 7 | 24 | 79 |
| Region of Enrollment(Participants) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Sweden | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Belgium | 2 | 2 | 3 | 1 | 0 | 0 | 0 | 2 | 3 | 13 |
| United States | 3 | 6 | 17 | 16 | 12 | 4 | 2 | 6 | 11 | 77 |
| Italy | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 2 | 6 |
| United Kingdom | 0 | 1 | 9 | 0 | 0 | 0 | 0 | 0 | 3 | 13 |
| France | 4 | 2 | 17 | 3 | 6 | 2 | 3 | 5 | 20 | 62 |
| Switzerland | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 7 | 10 |
| Germany | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Spain | 10 | 8 | 23 | 5 | 4 | 9 | 15 | 18 | 59 | 151 |
| Eastern Cooperative Oncology Group performance status(Participants) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 5 | 8 | 32 | 11 | 2 | 5 | 18 | 8 | 38 | 127 |
| 1 | 14 | 10 | 35 | 16 | 19 | 10 | 2 | 23 | 59 | 188 |
| 2 | 0 | 1 | 6 | 1 | 2 | 0 | 1 | 1 | 8 | 20 |
| Weight(kg) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Median | 72.2 (45.0 to 115.0) | 65.0 (50.1 to 108.2) | 70.0 (42.5 to 140.8) | 77.0 (51.0 to 127.7) | 78.5 (59.0 to 116.3) | 73.0 (49.0 to 107.0) | 65.5 (52.0 to 115.1) | 64.0 (47.0 to 121.0) | 71.0 (46.0 to 138.3) | 71.0 (42.5 to 140.8) |
| Height(cm) | Biliary Tract Carcinoma Cohort | Carcinoma of Unknown Primary Site Cohort | Endometrial Carcinoma Cohort | Ewing's Family of Tumors Cohort | Germ Cell Tumors Cohort | Head and Neck Carcinoma Cohort | BRCA1/2-associated Metastatic Breast Carcinoma Cohort | Neuroendocrine Tumors Cohort | Small Cell Lung Cancer Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Median | 168 (148 to 187) | 164.5 (141 to 187) | 161 (143 to 180) | 173 (155 to 193) | 177 (157 to 190) | 170 (155 to 186) | 163.0 (147 to 177) | 169 (150 to 190) | 167 (150 to 183) | 165 (141 to 193) |
15 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Sep 2020, 60 months.
Results were first posted in Nov 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183